Stockholders approve 336,667 share increase to Lixte's 2020 Stock Incentive Plan

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

At Nov 27 2023 annual meeting, shareholders voted to amend the 2020 Stock Incentive Plan, increasing authorized shares by 336,667 to 750,000.
All five director nominees elected with votes ranging from 856,934 to 905,489 for; broker non-votes 559,164.
Ratification of Weinberg & Company as auditor for FY2023 passed with 1,433,849 for, 40,266 against.
Stock Plan amendment approved: 854,971 for, 60,023 against, 559,164 broker non-votes.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LIXTE BIOTECHNOLOGY HOLDINGS, INC. shareholders approved Election of five director nominees to serve for a one-year term expiring at the 2024 annual meeting at the 2023-11-27 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-11-27

Exact text from the filing

The results of the voting were as follows: Proposal 1 (election of directors): Each of the director nominees to the Company’s Board of Directors was elected as follows: Nominee Votes For Votes Withheld Broker Non-Votes Dr. Stephen Forman 856,934 58,480 559,164 Dr. Yun Yen 904,748 10,666 559,164 Regina Brown 905,057 10,357 559,164 Dr. René Bernards 905,489 9,925 559,164 Bas van der Baan 865,224 50,190 559,164

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LIXTE BIOTECHNOLOGY HOLDINGS, INC. shareholders approved Approve amendment to the 2020 Stock Incentive Plan to increase common shares issuable by 336,667 shares to a total of 750,000 shares at the 2023-11-27 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-11-27

Exact text from the filing

Proposal 3 (amendment of the Stock Plan): Votes For Votes Against Abstain Broker Non-Votes 854,971 60,023 420 559,164

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LIXTE BIOTECHNOLOGY HOLDINGS, INC. shareholders approved Ratify the appointment of Weinberg & Company, P.A. as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-11-27 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-11-27

Exact text from the filing

Proposal 2 (appointment of accounting firm): Votes For Votes Against Abstain Broker Non-Votes 1,433,849 40,266 463 0

View on SEC.gov

560 shareholder votes filed in the last 30 days. Browse all shareholder votes →

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-042954

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.